{"organizations": [], "uuid": "3104ce04209d24c4a3fdfb2a5b846a54dd40250e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-aclaris-therapeutics-signs-agreeme/brief-aclaris-therapeutics-signs-agreement-with-james-alexander-corp-idUSFWN1PP1EY", "country": "US", "domain_rank": 408, "title": "BRIEF-Aclaris Therapeutics Signs Agreement With James Alexander Corp", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-30T23:57:00.000+02:00", "replies_count": 0, "uuid": "3104ce04209d24c4a3fdfb2a5b846a54dd40250e"}, "author": "", "url": "https://www.reuters.com/article/brief-aclaris-therapeutics-signs-agreeme/brief-aclaris-therapeutics-signs-agreement-with-james-alexander-corp-idUSFWN1PP1EY", "ord_in_thread": 0, "title": "BRIEF-Aclaris Therapeutics Signs Agreement With James Alexander Corp", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 30 (Reuters) - Aclaris Therapeutics Inc:\n* ACLARIS THERAPEUTICS SAYS ON JAN 24, CO ENTERED INTO COMMERCIAL SUPPLY MANUFACTURING SERVICES AGREEMENT WITH JAMES ALEXANDER CORP - SEC FILING\n* ACLARIS THERAPEUTICS INC - PURSUANT TO AGREEMENT, COMPANY MUST MEET A PRODUCT UNIT PURCHASE MINIMUM EACH YEAR BETWEEN 2018 AND 2022\n* ACLARIS THERAPEUTICS INC - DURING TERM OF AGREEMENT, JAMES ALEXANDER WILL NOT MANUFACTURE ANY COMPETITIVE PRODUCT, AS DEFINED IN AGREEMENT\n* ACLARIS-JAMES ALEXANDER TO EXCLUSIVELY MANUFACTURE FINISHED DOSAGE FORM OF CO‘S FDA-APPROVED ESKATA TOPICAL SOLUTION, 40% (W/W) PRODUCT FOR SALE\n* ACLARIS THERAPEUTICS - UNDER DEAL, GRANTED JAMES ALEXANDER ROYALTY-FREE, NON-EXCLUSIVE, NON-TRANSFERRABLE LICENSE OF CERTAIN OF INTELLECTUAL PROPERTY\n* ACLARIS THERAPEUTICS- IN EVENT THAT CO NOT MEET PURCHASE MINIMUM REQUIRED UNDER DEAL, JAMES ALEXANDER‘S EXCLUSIVITY OBLIGATION TO CO WILL CEASE\n* ACLARIS-AGREEMENT IS FIVE YEARS FROM THE DATE OF THE FIRST COMMERCIAL SALE OF ESKATA, THEREAFTER TO BE RENEWED AUTOMATICALLY FOR ONE-YEAR PERIODS Source text - bit.ly/2GwHMRp Further company coverage:\n ", "external_links": [], "published": "2018-01-30T23:57:00.000+02:00", "crawled": "2018-01-31T00:11:34.019+02:00", "highlightTitle": ""}